Jingqi Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jingqi Wu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chenhua Wang
State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
1 shared publication - Kun Zhang
Department of Histology and Developmental Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
1 shared publication - Lijian Hui
The Research Laboratory of Liver Molecular Pathology, Key Laboratory of Multi-cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China
1 shared publication - Ludi Zhang
Department of Pharmacology, Hebei Medical University
1 shared publication - Xiang Yuan
State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
1 shared publication - Zhen Sun
State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 11 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Hepatocyte transplantation: The progress and the challenges
Numerous studies have shown that hepatocyte transplantation is a promising approach for liver diseases, such as liver-based metabolic diseases and acute liver failure. However, it lacks strong evidence to support the long-term therapeutic effects of hepatocyte transplantation in clinical practice. Currently, major hurdles include availability of quality-assured hepatocytes, efficient engraftment and repopulation, and effective immunosuppressive regimens. Notably, cell sources have been advanced recently by expanding primary human hepatocytes by means of dedifferentiationin vitro. Moreover, the transplantation efficiency was remarkably improved by the established preparative hepatic irradiation in combination with hepatic mitogenic stimuli regimens. Finally, immunosuppression drugs, including glucocorticoid and inhibitors for co-stimulating signals of T cell activation, were proposed to prevent innate and adaptive immune rejection of allografted hepatocytes. Despite remarkable progress, further studies are required to improvein vitrocell expansion technology, develop clinically feasible preconditioning regimens, and further optimize immunosuppression regimens or establishex vivogene correction-based autologous hepatocyte transplantation.
- 11 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Open AccessHepatocyte transplantation: The progress and the challenges
Numerous studies have shown that hepatocyte transplantation is a promising approach for liver diseases, such as liver-based metabolic diseases and acute liver failure. However, it lacks strong evidence to support the long-term therapeutic effects of hepatocyte transplantation in clinical practice. Currently, major hurdles include availability of quality-assured hepatocytes, efficient engraftment and repopulation, and effective immunosuppressive regimens. Notably, cell sources have been advanced recently by expanding primary human hepatocytes by means of dedifferentiationin vitro. Moreover, the transplantation efficiency was remarkably improved by the established preparative hepatic irradiation in combination with hepatic mitogenic stimuli regimens. Finally, immunosuppression drugs, including glucocorticoid and inhibitors for co-stimulating signals of T cell activation, were proposed to prevent innate and adaptive immune rejection of allografted hepatocytes. Despite remarkable progress, further studies are required to improvein vitrocell expansion technology, develop clinically feasible preconditioning regimens, and further optimize immunosuppression regimens or establishex vivogene correction-based autologous hepatocyte transplantation.